Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 4/20 | 0.52 |
| ▸ | ESR2 known ✓ | Q92731 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 3/20 | 0.41 |
| ▸ | CES1 | P23141 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL29287419 | 1.00 | CYP3A4 (0.60) | CYP3A4TDP1ESR1ESR2CA2 | |
| Acetic Acid SCHEMBL366510 | 1.00 | CYP3A4 (0.60) | CYP3A4TDP1ESR1ESR2CA2 | |
| Acetic Acid SCHEMBL57505 | 1.00 | CYP3A4 (0.60) | CYP3A4TDP1ESR1ESR2CA2 | |
| Acetic Acid SCHEMBL7752539 | 0.98 | CYP3A4 (0.57) | CYP3A4TDP1ESR1ESR2CA2 | |
| Acetic Acid SCHEMBL3302716 | 0.98 | CYP3A4 (0.57) | CYP3A4TDP1ESR1ESR2CA2 | |
| Acetic Acid SCHEMBL28591790 | 0.98 | CYP3A4 (0.57) | CYP3A4TDP1ESR1ESR2CA2 | |
| Acetic Acid SCHEMBL3826322 | 0.95 | CYP3A4 (0.55) | CYP3A4TDP1ESR1ESR2CA2 | |
| Acetic Acid SCHEMBL8422529 | 0.95 | CYP3A4 (0.55) | CYP3A4TDP1ESR1ESR2CA2 | |
| Acetic Acid SCHEMBL8425843 | 0.95 | CYP3A4 (0.60) | CYP3A4TDP1ESR1ESR2CA2 | |
| Acetic Acid SCHEMBL8693165 | 0.95 | CYP3A4 (0.60) | CYP3A4TDP1ESR1ESR2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 972 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117206478-B | Surface oxidation-resistant color aluminum wire and preparation method and application thereof | 安徽捷澳电子有限公司 | 2026-05-22 | — | — | CN | claimed |
| EP-4584309-A1 | POLYCYCLIC-OLEFINIC POLYMERS CONTAINING ACRYLATE FUNCTIONALITY WITH ACRYLATE/MALEIMIDE CROSSLINKERS AS B-STAGEABLE COMPOSITIONS FOR LOW LOSS APPLICATIONS | Promerus, LLC (US) | 2025-07-16 | — | — | EP | claimed |
| EP-4090654-B1 | METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS | LUPIN LTD (IN) | 2025-07-09 | — | — | EP | claimed |
| US-12344592-B2 | Methods, processes and intermediates for preparing chroman compounds | LUPIN LIMITED (IN) | 2025-07-01 | — | — | US | claimed |
| CN-119453602-B | Anti-cutting glove and preparation method thereof | 江苏意进隆科技有限公司 | 2025-06-13 | — | — | CN | claimed |
| CN-120129654-A | Synthesis method of covalent bonding lattice | 卡斯西部储备大学 | 2025-06-10 | — | — | CN | claimed |
| CN-120058734-A | Acceptor unit with skeleton containing cyclic thiophene, thiophene 2-position bromination substitution and side chain alkyl substitution, and preparation and application thereof | 复旦大学 | 2025-05-30 | — | — | CN | claimed |
| CN-119968406-A | Polycyclic olefin polymers containing acrylate functionality and acrylate/maleimide crosslinkers as B-stageable compositions in low loss applications | 普罗米鲁斯有限责任公司 | 2025-05-09 | — | — | CN | claimed |
| CN-119930599-A | Preparation process of high-purity azilsartan medoxomil | 山东鲁宁药业有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-119264184-B | Preparation method of dideoxy ring-opened ribonucleotide triphosphate and intermediate | 天津奥利芙生物技术有限公司 | 2025-03-28 | — | — | CN | claimed |
| US-6201131-B1 | REACTING A 2-(ARYLSUFONYL) ETHANOL DERIVATIVE WITH AN ACID ANHYDRIDE IN PRESENCE OF A BASE, FURTHER REACTING THIS WITH AN AROMATIC HALIDE IN THE PRESENCE OF A PALLADIUM CATALYST; USEFUL AS INTERMEDIATES TO DRUGS, AGROCHEMICALS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-03-13 | — | — | US | claimed |
| EP-0783318-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-10-20 | — | — | EP | claimed |
| EP-0783318-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1997-07-16 | — | — | EP | claimed |
| WO-1996009836-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-04-04 | — | — | WO | claimed |
| EP-0643704-A4 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS. | — | 1995-04-12 | — | — | EP | claimed |
| EP-0643704-A1 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-03-22 | — | — | EP | claimed |
| EP-0468281-B1 | Substituted phenylacetylenes, pharmaceuticals containing them and methods for the preparation of these compounds and pharmaceuticals | GRUENENTHAL GMBH (DE) | 1995-03-08 | — | — | EP | claimed |
| US-5310928-A | Process for preparing biphenyltetrazole compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-05-10 | — | — | US | claimed |
| WO-1993010106-A1 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-05-27 | — | — | WO | claimed |
| US-4642392-A | Conjugated alkadiene telomerization to organo-oxyalkadienes | NATIONAL DISTILLERS AND CHEMICAL CORPORATION (US) | 1987-02-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344592-B2 | Methods, processes and intermediates for preparing chroman compounds | CASR, CALCR, RYR1 | ESR1 291/4885ESR2 727/4885CYP3A4 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.